Drug Profile

AGS 16C3F

Alternative Names: AGS-16C3F; AGS-16M8F; Anti-ENPP3-MMAF

Latest Information Update: 15 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Agensys
Developer Astellas Pharma
Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Renal cell carcinoma

Most Recent Events

14 Dec 2023 Seagen has been acquired by Pfizer
08 Oct 2020 Seattle Genetics is now called Seagen
26 Apr 2017 Agensys and Astellas Pharma completes a phase I trial for Renal cell carcinoma (Metastatic disease, Second-line therapy or greater) in USA (NCT01672775)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com